

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified
prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUIDB enhanced with new custom
IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.
applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008



NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:37:10 ON 10 APR 2008



```

chain nodes :
11 19
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16
chain bonds :
4-11 5-12 9-19
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 12-13 12-16 13-14 14-15 15-16

exact/norm bonds :
2-7 3-9 4-11 5-12 7-8 8-9 9-19 12-13 12-16 13-14 14-15 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 12 :
```

G1:C,O,S,N

G2:H,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:37:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 15 TO ITERATE

100.0% PROCESSED 15 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 68 TO 532

PROJECTED ANSWERS: 11 TO 389

L2 10 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:37:59 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 330 TO ITERATE

100.0% PROCESSED 330 ITERATIONS

215 ANSWERS

SEARCH TIME: 00.00.01

L3 215 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'CAPLUS' ENTERED AT 11:38:09 ON 10 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2008 VOL 148 ISS 15
FILE LAST UPDATED: 9 Apr 2008 (20080409/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:330210 CAPLUS

DOCUMENT NUMBER: 146:337882

TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase IV inhibitors

INVENTOR(S): Palle, Venakta P.; Balachandran, Sarala; Gupta, Nidhi; Khairnar, Vinayak Vasantrao; Ramaiah, Raghu; Ray, Abhijit; Dastidar, Sunanda Ghose

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 37pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007031838	A1	20070322	WO 2006-IB2494	20060911
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: IN 2005-DE2522 A 20050916

OTHER SOURCE(S): MARPAT 146:337882

GI



AB Title compds. [I; P = atoms to form a 6-membered ring containing 1-3 double bonds; M = atoms to form a 5-membered ring containing 1-2 double bonds; X1, X2 = C; X3 = N; R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, etc.; R2 = H, alkyl, halo, cyano, NO₂, amino, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; R3 = (substituted) amino, acylamino; R4 = substituted dihydroisoxazolyl], were prepared Thus, a stirred mixture of Me methacrylate and 4-cyclopropylamino-1-ethyl-1H-pyrazolo[3.4-b]pyridine-5-carboxaldehyde oxime (preparation given) in THF was treated with aqueous NaOCl over 5 min followed by stirring for 4 h to give 51% Me 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-5-methyl-4,5-dihydroisoxazole-5-carboxylate.

IT 929633-30-7P 929633-31-8P 929633-32-9P

929633-33-0P 929633-34-1P 929633-35-2P

929633-37-4P 929633-39-6P 929633-41-0P


929633-50-1P 929633-56-7P 929633-57-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyrazolopyridines as phosphodiesterase IV inhibitors)


RN 929633-30-7 CAPLUS

CN 5-Isoxazolecarboxylic acid, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl-, methyl ester (CA INDEX NAME)




RN 929633-31-8 CAPLUS

CN 5-Isoxazolemethanol, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-32-9 CAPLUS

CN 5-Isoxazolecarbonitrile, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-33-0 CAPLUS

CN 5-Isoxazoleacetic acid, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




RN 929633-34-1 CAPLUS

CN 5-Isoxazoleacetic acid, 5-carboxy-3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro- (CA INDEX NAME)




RN 929633-35-2 CAPLUS

CN 5-Isoxazoleacetamide, 5-(aminocarbonyl)-3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro- (CA INDEX NAME)




RN 929633-37-4 CAPLUS

CN 5(4H)-Isoxazoleethanol, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-5-(hydroxymethyl)- (CA INDEX NAME)




RN 929633-39-6 CAPLUS

CN 5-Isioxazolecaboxamide, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-41-0 CAPLUS

CN 5-Isioxazolecaboxylic acid, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-50-1 CAPLUS

CN 5-Isioxazolecaboxylic acid, 3-[4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl-, methyl ester (CA INDEX NAME)




RN 929633-56-7 CAPLUS

CN 5-Isioxazoleacetic acid, 3-[4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)



RN 929633-57-8 CAPLUS

CN 5-Isioxazolemethanol, 3-[4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:550957 CAPLUS
 DOCUMENT NUMBER: 141:106464
 TITLE: Preparation of pyrazolo[3,4-b]pyridine derivatives for use in pharmaceutical compositions as phosphodiesterase inhibitors
 INVENTOR(S): Allen, David George; Coe, Diane Mary; Cook, Caroline Mary; Cooper, Anthony William James; Dowle, Michael Dennis; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 244 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056823	A1	20040708	WO 2003-EP14867	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511340	A1	20040708	CA 2003-2511340	20031219
AU 2003293999	A1	20040714	AU 2003-293999	20031219
EP 1581532	A1	20051005	EP 2003-789413	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017645	A	20051206	BR 2003-17645	20031219
CN 1751042	A	20060322	CN 2003-80109835	20031219
JP 2006513258	T	20060420	JP 2005-502565	20031219
AU 2004299277	A1	20050630	AU 2004-299277	20041217
CA 2557004	A1	20050630	CA 2004-2557004	20041217
WO 2005058892	A1	20050630	WO 2004-EP14490	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1737857	A1	20070103	EP 2004-804089	20041217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1914205	A	20070214	CN 2004-80041657	20041217
JP 2007514704	T	20070607	JP 2006-544380	20041217
ZA 2005005074	A	20060927	ZA 2005-5074	20050622
IN 2005KN01207	A	20070713	IN 2005-KN1207	20050622


MX 2005PA06923	A	20050818	MX 2005-PA6923	20050623
NO 2005003600	A	20050822	NO 2005-3600	20050722
US 20060252790	A1	20061109	US 2006-540371	20060221
US 20070111995	A1	20070517	US 2006-596561	20060616
IN 2006KN01988	A	20070518	IN 2006-KN1988	20060714
NO 2006003340	A	20060912	NO 2006-3340	20060718

PRIORITY APPLN. INFO.:

GB 2002-30045	A	20021223
GB 2002-30165	A	20021224
GB 2003-7998	A	20030407
WO 2003-EP14867	W	20031219
WO 2003-EP314867	A	20031219
GB 2004-5899	A	20040316
GB 2004-5936	A	20040316
GB 2004-6754	A	20040325
WO 2004-EP14490	W	20041217

OTHER SOURCE(S): MARPAT 141:106464

GI



AB Pyrazolo[3,4-b]pyridine derivs., such as I [R = heterocyclyl; R¹ = (CH₂)₂OH, alkyl, fluoroalkyl; R² = H, Me, fluoroalkyl; R³ = alkyl, (un)substituted-Ph, cycloalkyl, heterocyclyl, etc.; R^{3a} = H, alkyl], were prepared for therapeutic uses as inhibitors of phosphodiesterase, particularly phosphodiesterase IV (PDE4). These pyrazolo[3,4-b]pyridines were claimed for use in the treatment and/or prophylaxis of cognitive impairment and inflammatory and/or allergic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis. Thus, pyrazolo[3,4-b]pyridine derivative II was prepared via a cyclocondensation reaction of hydrazide III using POCl₃ in MeCN. The prepared pyrazolo[3,4-b]pyridine were assayed for PDE4 inhibitory activity, and systems for delivery of these PDE4 inhibitors were discussed.

IT 720706-29-6P 720706-30-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridine derivs. for use in pharmaceutical compns. as phosphodiesterase inhibitors)

RN 720706-29-6 CAPLUS


CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-

pyrazolo[3,4-b]pyridin-5-yl]-N-[[1-(methylamino)cyclohexyl]methyl]- (CA INDEX NAME)



RN 720706-30-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-[(3-methoxyphenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



IT 720705-76-0P 720705-77-1P 720706-05-8P

720706-06-9P 720706-07-0P 720706-08-1P


720706-10-5P 720706-11-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrazolo[3,4-b]pyridine derivs. for use in pharmaceutical compns. as phosphodiesterase inhibitors)

RN 720705-76-0 CAPLUS


CN 1,2,4-Oxadiazole-3-acetic acid, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720705-77-1 CAPLUS
 CN 1,2,4-Oxadiazole-3-acetic acid, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720706-05-8 CAPLUS
 CN Carbamic acid, [[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 720706-06-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[3-(aminomethyl)-1,2,4-oxadiazol-5-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720706-07-0 CAPLUS
 CN Butanamide, 4-chloro-N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-

pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl)methyl]- (CA INDEX NAME)




RN 720706-08-1 CAPLUS

CN Pentanamide, 5-chloro-N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl)methyl]- (CA INDEX NAME)



RN 720706-10-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720706-11-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-(4-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)-, monohydrochloride

(9CI) (CA INDEX NAME)




● HCl


IT 720703-79-7P 720703-95-7P 720705-31-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolo[3,4-b]pyridines for use in pharmaceutical compns. as phosphodiesterase inhibitors)
RN 720703-79-7 CAPLUS
CN 4-Oxazolecarboxylic acid, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-, methyl ester (CA INDEX NAME)



RN 720703-95-7 CAPLUS
CN 4-Oxazolecarboxylic acid, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 720705-31-7 CAPLUS
 CN 4-Oxazolecarboxylic acid, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-, methyl ester (CA INDEX NAME)



IT 720703-37-7P 720703-38-8P 720703-39-9P
 720703-40-2P 720703-41-3P 720703-42-4P
 720703-43-5P 720703-44-6P 720703-45-7P
 720703-47-9P 720703-48-0P 720703-49-1P
 720703-50-4P 720703-51-5P 720703-52-6P
 720703-53-7P 720703-54-8P 720703-55-9P
 720703-56-0P 720703-57-1P 720703-58-2P
 720703-59-3P 720703-60-6P 720703-62-8P
 720703-63-9P 720703-64-0P 720703-65-1P
 720703-66-2P 720703-67-3P 720703-68-4P
 720703-69-5P 720703-70-8P 720703-71-9P
 720703-72-0P 720703-73-1P 720703-74-2P
 720703-75-3P 720703-76-4P 720703-77-5P
 720703-78-6P 720703-80-0P 720703-81-1P
 720703-82-2P 720703-83-3P 720703-84-4P
 720703-85-5P 720703-86-6P 720703-87-7P
 720703-88-8P 720703-89-9P 720703-90-2P
 720703-91-3P 720703-92-4P 720703-93-5P
 720703-94-6P 720703-96-8P 720703-97-9P
 720703-98-0P 720703-99-1P 720704-00-7P
 720704-01-8P 720704-03-0P 720704-04-1P
 720704-05-2P 720704-06-3P 720704-07-4P
 720704-08-5P 720704-09-6P 720704-10-9P
 720704-11-0P 720704-12-1P 720704-13-2P
 720704-14-3P 720704-15-4P 720704-16-5P
 720704-17-6P 720704-18-7P 720704-19-8P
 720704-20-1P 720704-21-2P 720704-22-3P


720704-23-4P 720704-24-5P 720704-25-6P
 720704-26-7P 720704-27-8P 720704-28-9P
 720704-29-0P 720704-30-3P 720704-31-4P
 720704-32-5P 720704-33-6P 720704-34-7P
 720704-35-8P 720704-36-9P 720704-37-0P
 720704-38-1P 720704-39-2P 720704-40-5P
 720704-41-6P 720704-42-7P 720704-43-8P
 720704-44-9P 720704-45-0P 720704-46-1P
 720704-47-2P 720704-48-3P 720704-49-4P
 720704-50-7P 720704-51-8P 720704-52-9P
 720704-53-0P 720704-54-1P 720704-56-3P
 720704-57-4P 720704-58-5P 720704-59-6P
 720704-60-9P 720704-61-0P 720704-62-1P
 720704-63-2P 720704-64-3P 720704-65-4P
 720704-66-5P 720704-67-6P 720704-68-7P
 720704-69-8P 720704-70-1P 720704-71-2P
 720704-72-3P 720704-73-4P 720704-74-5P
 720704-75-6P 720704-76-7P 720704-77-8P
 720704-78-9P 720704-79-0P 720704-80-3P
 720704-81-4P 720704-82-5P 720704-83-6P
 720704-84-7P 720704-85-8P 720704-86-9P
 720704-87-0P 720704-88-1P 720704-89-2P
 720704-90-5P 720704-91-6P 720704-92-7P
 720704-93-8P 720704-94-9P 720704-95-0P
 720704-96-1P 720704-97-2P 720704-98-3P
 720704-99-4P 720705-00-0P 720705-01-1P
 720705-02-2P 720705-03-3P 720705-04-4P
 720705-05-5P 720705-06-6P 720705-07-7P
 720705-08-8P 720705-09-9P 720705-10-2P
 720705-11-3P 720705-12-4P 720705-13-5P
 720705-14-6P 720705-15-7P 720705-16-8P
 720705-17-9P 720705-18-0P 720705-19-1P
 720705-20-4P 720705-21-5P 720705-22-6P
 720705-23-7P 720705-24-8P 720705-25-9P
 720705-26-0P 720705-27-1P 720705-28-2P
 720705-29-3P 720708-62-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolo[3,4-b]pyridines for use in pharmaceutical compns.
 as phosphodiesterase inhibitors)


RN 720703-37-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-
 oxadiazol-2-yl)- (CA INDEX NAME)




RN 720703-38-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclopentyl-1-ethyl-5-[5-
 [(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720703-39-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclopentyl-1-ethyl-5-[5-(1-methylethyl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720703-40-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 720703-41-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclopentyl-1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)




RN 720703-42-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclopentyl-1-ethyl-5-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 720703-43-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-N-(4-fluorophenyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)




RN 720703-44-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclopentyl-5-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)-1-ethyl- (CA INDEX NAME)




RN 720703-45-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(1-methylethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-47-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclohexyl-1-ethyl-5-[5-(1-methylethyl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720703-48-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(1-methylethyl)-1,3,4-oxadiazol-2-yl]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 720703-49-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methylpropyl)- (CA INDEX NAME)




RN 720703-50-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclohexyl-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)



RN 720703-51-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-52-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-[(1R)-1,2-dimethylpropyl]-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-53-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-[(1S)-1,2-dimethylpropyl]-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-54-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-55-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclohexyl-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl- (CA INDEX NAME)



RN 720703-56-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclopentyl-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl- (CA INDEX NAME)




RN 720703-57-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(2-methylpropyl)- (CA INDEX NAME)



RN 720703-58-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-N-[(1S)-1,2-dimethylpropyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-59-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-N-[(1R)-1,2-dimethylpropyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-60-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-62-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-cyclohexyl-1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)



RN 720703-63-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-N-(2-methylpropyl)-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)



RN 720703-64-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-[(1S)-1,2-dimethylpropyl]-1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-65-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, N-[(1R)-1,2-dimethylpropyl]-1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-66-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-67-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-68-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[3-[(dimethylamino)methyl]-1,2,4-oxadiazol-5-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-69-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-(4-morpholinylmethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-70-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-71-9 CAPLUS
 CN 4-Piperidinamine, 1-acetyl-N-[1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)




RN 720703-72-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(3-methyl-3-oxetanyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-73-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-74-2 CAPLUS
 CN 1,3,4-Oxadiazole-2-carboxamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 720703-75-3 CAPLUS
 CN 2-Pyrrolidinone, 4-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]-1-methyl- (CA INDEX NAME)




RN 720703-76-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(tetrahydro-2H-pyran-4-yl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720703-77-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(4-morpholinylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-78-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-[(1,1-dimethylethoxy)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-80-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-(4,5-dihydro-4-methyl-2-oxazolyl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-81-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-(5-methyl-1,3,4-oxadiazol-2-yl)-1-propyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-82-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(tetrahydro-2-furanyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-83-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(dimethylamino)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-84-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 720703-85-5 CAPLUS

CN 4-Piperidinamine, 1-acetyl-N-[1-ethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 720703-86-6 CAPLUS


CN 4-Piperidinamine, 1-acetyl-N-[1-ethyl-5-[3-(4-morpholinylmethyl)-1,2,4-oxadiazol-5-yl]-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 720703-87-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[(4R)-4,5-dihydro-4-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-88-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[(4S)-4,5-dihydro-4-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-89-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[(4S)-4,5-dihydro-4-(phenylmethyl)-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-90-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[(4R)-4,5-dihydro-4-(phenylmethyl)-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-91-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[(4S,5R)-4,5-dihydro-5-methyl-4-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-92-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[(5R)-4,5-dihydro-5-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 720703-93-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[(5S)-4,5-dihydro-5-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 720703-94-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-
 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-96-8 CAPLUS
 CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridin-5-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 720703-97-9 CAPLUS
 CN Morpholine, 4-[[2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridin-5-yl]-4-oxazolyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 720703-98-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-N-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-99-1 CAPLUS


CN Cyclohexanol, 4-[[1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 720704-00-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(tetrahydro-2H-pyran-3-yl)- (CA INDEX NAME)




RN 720704-01-8 CAPLUS

CN Cyclohexanone, 4-[[1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]- (CA INDEX NAME)




RN 720704-03-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-propyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-04-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-6-methyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-05-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-6-methyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(tetrahydro-2H-pyran-4-yl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-06-3 CAPLUS

1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-07-4 CAPLUS

CN 2-Pyrrolidinone, 5-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-08-5 CAPLUS

CN Acetamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]- (CA INDEX NAME)




RN 720704-09-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(1-methyl-2-piperidin-4-yl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-10-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-11-0 CAPLUS


CN Cyclopentanone, 3-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-12-1 CAPLUS

CN 2-Thiazolidinone, 4-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 720704-13-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(2,2-dimethylcyclopropyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-14-3 CAPLUS
 CN Acetamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]-N-methyl- (CA INDEX NAME)




RN 720704-15-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-[(tetrahydro-2H-pyran-4-yl)methyl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-16-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(1-methylcyclobutyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-17-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(3-methyl-5-isoxazolyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-18-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-19-8 CAPLUS

CN Piperidine, 1-acetyl-4-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 720704-20-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-[(4-methyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-21-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-22-3 CAPLUS
 CN Pyrrolidine, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 720704-23-4 CAPLUS
 CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-phenyl- (CA INDEX NAME)




RN 720704-24-5 CAPLUS
 CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(1-phenylethyl)- (CA INDEX NAME)




RN 720704-25-6 CAPLUS
 CN Piperidine, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 720704-26-7 CAPLUS
 CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 720704-27-8 CAPLUS
 CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 720704-28-9 CAPLUS
 CN 1,2,4-Oxadiazole-3-acetamide, N-ethyl-5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-29-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-[1-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-30-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[3-(cyclohexylmethyl)-1,2,4-oxadiazol-5-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-31-4 CAPLUS

CN Morpholine, 4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 720704-32-5 CAPLUS

CN Piperazine, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 720704-33-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(1H-1,2,3-triazol-1-ylmethyl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-34-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-[(2,4-dimethyl-5-thiazolyl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-35-8 CAPLUS
 CN Formic acid, compd. with 5-[5-[(2,4-dimethyl-5-thiazolyl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)
 CM 1
 CRN 720704-34-7
 CMF C21 H25 N7 O2 S



CM 2
 CRN 64-18-6
 CMF C H2 O2




RN 720704-36-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(2-furanylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-37-0 CAPLUS
 CN Formic acid, compd. with 1-ethyl-5-[5-(2-furanylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1)
 (CA INDEX NAME)

CM 1

CRN 720704-36-9
 CMF C20 H22 N6 O3




CM 2

CRN 64-18-6
 CMF C H2 O2

$\text{O}=\text{CH}-\text{OH}$


RN 720704-38-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(3-isoxazolylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-39-2 CAPLUS
 CN Formic acid, compd. with 1-ethyl-5-[5-(3-isoxazolylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1)
 (CA INDEX NAME)


CM 1

CRN 720704-38-1
 CMF C19 H21 N7 O3




CM 2

CRN 64-18-6
 CMF C H2 O2



RN 720704-40-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(4-methoxyphenyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-41-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(4-methoxyphenyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 720704-40-5


CMF C23 H26 N6 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 720704-42-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(1H-tetrazol-1-ylmethyl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-43-8 CAPLUS

CN Formic acid, compd. with 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(1H-tetrazol-1-ylmethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)

CM 1

CRN 720704-42-7

CMF C17 H20 N10 O2



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 720704-44-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(5-isothiazolylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-45-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(3-methyl-5-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-46-1 CAPLUS

CN Formic acid, compd. with 1-ethyl-5-[5-[(3-methyl-5-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)

CM 1

CRN 720704-45-0


CMF C20 H23 N7 O3



CM 2


CRN 64-18-6

CMF C H2 O2




RN 720704-47-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-[[4-(dimethylamino)phenyl]methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-48-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(2-methyl-4-thiazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-49-4 CAPLUS

CN Formic acid, compd. with 1-ethyl-5-[5-[(2-methyl-4-thiazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)

CM 1

CRN 720704-48-3


CMF C20 H23 N7 O2 S



CM 2


CRN 64-18-6

CMF C H2 O2



RN 720704-50-7 CAPLUS

CN Cyclopentaneacetamide, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl)methyl]-N-methyl-
(CA INDEX NAME)



RN 720704-51-8 CAPLUS


CN Cyclopentaneacetamide, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-

1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]-N-methyl-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 720704-50-7


CMF C24 H33 N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 720704-52-9 CAPLUS

CN Cyclopropanecarboxamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]-
(CA INDEX NAME)



RN 720704-53-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(5-methyl-3-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-(CA INDEX NAME)




RN 720704-54-1 CAPLUS

CN Formic acid, compd. with 1-ethyl-5-[5-[(5-methyl-3-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)

CM 1

CRN 720704-53-0


CMF C20 H23 N7 O3



CM 2


CRN 64-18-6

CMF C H2 O2



RN 720704-56-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[2-(4-methyl-5-thiazolyl)ethyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-57-4 CAPLUS

CN Formic acid, compd. with 1-ethyl-5-[5-[2-(4-methyl-5-thiazolyl)ethyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)

CM 1

CRN 720704-56-3


CMF C21 H25 N7 O2 S



RN 720704-59-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-[(3,5-dimethyl-4-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 720704-58-5
 CMF C21 H25 N7 O3




CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 720704-60-9 CAPLUS
 CN Acetamide, N-[1-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]ethyl]- (CA INDEX NAME)




RN 720704-61-0 CAPLUS
 CN Piperidine, 1-acetyl-4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 720704-62-1 CAPLUS
 CN Piperidine, 1-acetyl-4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 720704-61-0
 CMF C23 H31 N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 720704-63-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(4-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-64-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-65-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-66-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(2,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-67-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-[(4-bromophenyl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-68-7 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 720704-69-8 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 720704-70-1 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 720704-71-2 CAPLUS


CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 720704-72-3 CAPLUS
 CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 720704-73-4 CAPLUS
 CN 4-Oxazolecarboxamide, N-[(4-chlorophenyl)methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-74-5 CAPLUS
 CN 4-Oxazolecarboxamide, N-[(2,3-dimethylphenyl)methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-75-6 CAPLUS
 CN 4-Oxazolecarboxamide, N-[(3,5-dimethylphenyl)methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 720704-76-7 CAPLUS
 CN 4-Oxazolecarboxamide, N-[(3,4-dimethylphenyl)methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-77-8 CAPLUS
 CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(1-phenylethyl)- (CA INDEX NAME)



RN 720704-78-9 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720704-79-0 CAPLUS


CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720704-80-3 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(4-methylphenyl)- (CA INDEX NAME)




RN 720704-81-4 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)




RN 720704-82-5 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 720704-83-6 CAPLUS

CN 4-Oxazolecarboxamide, N-(1-acetyl-4-piperidinyl)-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-84-7 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-85-8 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 720704-86-9 CAPLUS


CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 720704-87-0 CAPLUS
 CN 4-Oxazolecarboxamide, N-[1-(aminomethyl)cyclohexyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-methyl- (CA INDEX NAME)



RN 720704-88-1 CAPLUS
 CN 4-Oxazolecarboxamide, N-(2,6-dimethylphenyl)-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-89-2 CAPLUS
 CN 4-Oxazolecarboxamide, N-[[4-(aminocarbonyl)phenyl]methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-90-5 CAPLUS

CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-91-6 CAPLUS

CN Morpholine, 4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]acetyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 720704-92-7 CAPLUS

CN Piperidine, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 720704-93-8 CAPLUS

CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(2-methoxy-1-methylethyl)- (CA INDEX NAME)




RN 720704-94-9 CAPLUS

CN Piperidine, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]acetyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 720704-95-0 CAPLUS

CN Piperidine, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]acetyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 720704-96-1 CAPLUS

CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-3-pyridinyl- (CA INDEX NAME)




RN 720704-97-2 CAPLUS

CN 2-Piperidinone, 6-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-98-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(5-methyl-1H-1,2,4-triazol-3-yl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-(9CI) (CA INDEX NAME)



RN 720704-99-4 CAPLUS
 CN Acetamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-00-0 CAPLUS
 CN Benzamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-01-1 CAPLUS

CN Benzeneacetamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-02-2 CAPLUS

CN Propanamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-2-methyl- (CA INDEX NAME)



RN 720705-03-3 CAPLUS


CN Butanamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-3-methyl- (CA INDEX NAME)



RN 720705-04-4 CAPLUS


CN Cyclohexanecarboxamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)

NAME)




RN 720705-05-5 CAPLUS

CN 2-Furancarboxamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-06-6 CAPLUS

CN Methanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-07-7 CAPLUS

CN Benzenesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-08-8 CAPLUS

CN Benzenemethanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-09-9 CAPLUS

CN 2-Propanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-10-2 CAPLUS

CN 1-Propanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-11-3 CAPLUS

CN Cyclopropanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-12-4 CAPLUS

CN 2-Thiophenesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-13-5 CAPLUS


CN 2-Pyrrolidinone, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-14-6 CAPLUS
 CN 2-Piperidinone, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 720705-15-7 CAPLUS
 CN Piperidine, 1-acetyl-4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 720705-16-8 CAPLUS
 CN Piperidine, 4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-1-(3-methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)




RN 720705-17-9 CAPLUS

CN Piperidine, 4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 720705-18-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-[1-(phenylsulfonyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-19-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-(phenylmethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-20-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-(1-phenylethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-21-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-[(4-methoxyphenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-22-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[3-[[4-(dimethylamino)phenyl]methyl]-1,2,4-oxadiazol-5-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-23-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[3-[[3-(dimethylamino)phenyl]methyl]-1,2,4-oxadiazol-5-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-24-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-(phenoxy)methyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-25-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[3-[(5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyridin-3-yl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 720705-26-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-[(4-phenyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-27-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-28-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-[[4-(dimethylamino)phenyl]methyl]-1,2,4-oxadiazol-3-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-29-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(4-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720708-62-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(tetrahydro-3-furanyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

11.86

190.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.60

-1.60

STN INTERNATIONAL LOGOFF AT 11:39:28 ON 10 APR 2008